Background & Aims

Pain is the low back, the most common site of pain in the body, is considered as chronic low back pain ( CLBP) .The main reason for CLBP is dysfunction of central pain pathways. Conventional treatment Options for chronic low back pain are acetaminophen, NSAIDs and opioids. However, they do not act at the root cause of the pain and have side effects in the long term.

Methods

A review was carried out to cover the existing clinical research on Duloxetine, a serotonin and norepinephrine reuptake inhibitor, in the therapy of chronic low back pain, including pharmacokinetics drug- drug interaction, case reports and special considerations. Our review was aimed at encompassing the bulk of Clinical research on Duloxetine, which included clinical trials, coadministration studies, case reports and cost effective studies.

Results

Highly effective in Chronic low back pain
Study type Randomized
Drug used : Duloxetine 60mg/ day
Number of patients: 456 patients with low back pain persists for at least 6 months.

Duration, : 14 weeks.
Results = 94.4% of patients more than 30% pain reduction and 82.4% of patients more than 50% pain reduction.
This ensures control of Chronic low back pain.

Excellent safety in patients with chronic low back pain
Study type: 5 Randomized trials; Drug used: Duloxetine 60 -120 mg/day.
No. Of patients : 625 patients with chronic low back pain
Duration: 4 weeks.
Results = 0% incidence of gastrointestinal, renal or cardiovascular side effects.
0% incidence of durg abuse and addiction. Thus proves a safer treatment option in chronic low back pain.

Conclusions

Highly effective in reducing chronic low back pain as well as other chronic musculoskeletal pain. This is safe and devoid of Side effects of NSAIDs and opioids and has anti depressant efficacy. The development of Duloxetine allows further optimisation of individual treatment strategies so as to provide more therapeutic choices in this medical domain.

References

1. Journal of Pain Research 2017 : 10 2157 _ 2167
2. Hirase T
3 Hirase j, ling J, et al
4.Incepta pharmaceuticals Bangladesh
5.S, Takahashi, A probable case of mirogabalin induced neutropenia
6. Current Medical Research and Opinion vol no 35 no 10
7. Journal of Pain research vol ,volume 13

Presenting Author

Shariar Ahmed

Poster Authors

SHARIAR AHMED

Lead Author

E-mail

Topics

  • Assessment and Diagnosis